Denosumab In Ebv Nasopharyngeal Carcinoma As A Model For RankMediated Immunologic Modulation Of Virus-Related Tumours (Dern)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03923842 |
|
Recruitment Status : Unknown
Verified February 2020 by Gruppo Oncologico del Nord-Ovest.
Recruitment status was: Recruiting
First Posted : April 23, 2019
Last Update Posted : February 17, 2020
|
Sponsor:
Gruppo Oncologico del Nord-Ovest
Collaborator:
Mario Negri Institute for Pharmacological Research
Information provided by (Responsible Party):
Gruppo Oncologico del Nord-Ovest
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Unknown |
|---|---|
| Estimated Primary Completion Date : | September 30, 2021 |
| Estimated Study Completion Date : | October 30, 2022 |